ID: ALA193428

Max Phase: Preclinical

Molecular Formula: C27H25N5O3

Molecular Weight: 467.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1nn(Cc2ccccc2)c(=O)c2nc(CCCCC(=O)O)n3nc(-c4ccccc4)cc3c12

Standard InChI:  InChI=1S/C27H25N5O3/c1-18-25-22-16-21(20-12-6-3-7-13-20)30-32(22)23(14-8-9-15-24(33)34)28-26(25)27(35)31(29-18)17-19-10-4-2-5-11-19/h2-7,10-13,16H,8-9,14-15,17H2,1H3,(H,33,34)

Standard InChI Key:  SHUOUDPXEIPOQQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 467.53

Molecular Weight (Monoisotopic): 467.1957

AlogP: 4.26

#Rotatable Bonds: 8

Polar Surface Area: 102.38

Molecular Species: ACID

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.72

CX Basic pKa:

CX LogP: 4.37

CX LogD: 1.07

Aromatic Rings: 5

Heavy Atoms: 35

QED Weighted: 0.34

Np Likeness Score: -1.17

References

1. Feixas J, Giovannoni MP, Vergelli C, Gavaldà A, Cesari N, Graziano A, Dal Piaz V..  (2005)  New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.,  15  (9): [PMID:15837329] [10.1016/j.bmcl.2005.02.090]

Source

Source(1):

• Scientific Literature